Thus the current in vitro human evidence, the mouse and sheep in vivo data, and the favourable safety profile in human subjects suggest that clinical trials of KCa3.1 blockade in IPF should be considered seriously. This evidence concerns the gene KCNN4 and idiopathic pulmonary fibrosis.